An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in Combination With Ipilimumab in Subjects With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CheckMate 592
- Sponsors Bristol-Myers Squibb
- 07 Apr 2017 Planned End Date changed from 1 Oct 2021 to 29 Sep 2021.
- 24 Mar 2017 Planned End Date changed from 1 Sep 2021 to 1 Oct 2021.
- 16 Mar 2017 Status changed from not yet recruiting to recruiting.